FMT plus pembrolizumab for advanced lung cancer after prior treatment
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This Phase 2 trial studies whether adding fecal microbiome transplant (FMT) to pembrolizumab can help people with advanced, PD-L1–positive non-small cell lung cancer that has returned or progressed after anti–PD-1/PD-L1 therapy. You may be asked to give new tumor tissue and undergo gut procedures, because the study aims to change gut bacteria to boost the immune response.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have stage IV non-small cell lung cancer with PD-L1 at 1% or higher on a specific tumor test (IHC using an FDA-approved method).
- Your cancer progressed after at least 2 doses of an anti–PD-1/PD-L1 medicine (you may still qualify if progression happened soon after certain prior treatments).
- You have measurable disease on scans and you can provide a new tumor biopsy (from a spot not previously irradiated).
- Your brain (if involved) must be treated and stable, and you must not have leptomeningeal spread of cancer in the brain covering layers.
- You can safely undergo bowel prep plus repeated FMT treatments (endoscopy and pill form) and understand infection/allergy risks.
- You are well enough for treatment (ECOG performance status 0–1) and have adequate organ function; screening checks include hepatitis viruses and HIV.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether giving patients a fecal microbiota transplant (healthy bacteria from stool of patients who responded to immunotherapy) before standard immunotherapy is safe and feasible for stage II-III lung cancer. It may improve how well the immune system fights cancer.
This trial tests whether a fecal microbiota transplant (FMT) — transferring healthy bacteria from a donor's stool into your gut — combined with the immunotherapy drug tislelizumab can help treat advanced non-small cell lung cancer (NSCLC) that has progressed after prior treatments. It aims to see if this combination can improve outcomes by boosting your immune system's response.
This trial tests a new study drug called PF-08634404 combined with standard chemotherapy for people with advanced lung cancer that has not been treated before. It aims to see if this combination works better than chemotherapy alone.
This Phase 1 study tests pembrolizumab (an immunotherapy) given together with a chemotherapy drug to treat non-small cell lung cancer that is locally advanced or has spread. It’s aimed at people who can handle treatment with an ECOG performance status of 2, including some with certain types of brain metastases.
This trial tests whether combining pembrolizumab (an immune treatment) with a lung ablation procedure can be safer and more effective for advanced non-small cell lung cancer after standard first treatment fails or the cancer comes back. It may help shrink tumors and improve control of the disease.
This trial studies whether giving a PD-1 antibody together with standard chemotherapy before surgery can improve outcomes for people with stage IIIB–IIIC non-small cell lung cancer. It aims to shrink or control the cancer and make treatment before surgery more effective.
Hear when a new Non Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.